Mary Elizabeth Klein

Title: Mary Elizabeth Klein: Innovator in Cancer Treatment

Introduction

Mary Elizabeth Klein is a prominent inventor based in New York, NY (US). She has made significant contributions to the field of cancer treatment through her innovative research and development of diagnostic tools. Her work focuses on improving the effectiveness of cancer therapies, particularly those involving CDK4 inhibitors.

Latest Patents

Mary Elizabeth Klein holds a patent for a companion diagnostic for CDK4 inhibitors. This invention relates to the use of one or more biomarkers to evaluate the likelihood that a CDK4 inhibitor would produce an anti-cancer effect in a subject. The invention is based on the discovery that cancer treatment with a CDK4 inhibitor is more effective when treated cancer cells undergo cellular senescence rather than a transient cell cycle arrest. This cellular senescence is associated with decreased MDM2 protein levels. The patent provides methods, compositions, and kits for a companion diagnostic for CDK4 inhibitors, particularly focusing on MDM2 expression as a biomarker for successful cancer treatment through CDK4 inhibition.

Career Highlights

Mary Elizabeth Klein is affiliated with the Memorial Sloan Kettering Cancer Center, where she continues her research and development efforts. Her work has been instrumental in advancing the understanding of cancer treatment and improving patient outcomes.

Collaborations

Some of her notable coworkers include Andrew C. Koff and Aimee Crago. Their collaborative efforts contribute to the ongoing research and innovation in cancer therapies.

Conclusion

Mary Elizabeth Klein is a dedicated inventor whose work in cancer diagnostics and treatment has the potential to significantly impact patient care. Her innovative approach to utilizing biomarkers for CDK4 inhibitors exemplifies the importance of research in the fight against cancer.